Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor infiltrating lymphocytes LM103

A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patient's resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs LM103 specifically recognize and kill the patient's tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous TILs LM103
Code name:LM 103
LM-103
LM103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search